MANGALAM GLOBAL ENT Latest Share Price (MGEL)
TODAY IN ONE LINE
MGEL fell 2.1% on above-average volume (494385.0x avg), lagging Nifty's -0.8% move, supported by recent strong earnings.
With a market cap of ₹511.14 Cr., it trades at a P/E of 10.31. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
MANGALAM GLOBAL ENT flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Consistent GrowthEPS compounded at 29.0% over 3 years
- ●Quarterly OutperformanceLatest quarter Sales up 19.3% and Profit up 11.9%
- ●Strong Return on EquityHealthy ROE of 17.5%
- ●Reasonable ValuationTrading at a moderate P/E of 11.7x
- ●High Promoter HoldingPromoters hold 72.4% skin-in-the-game
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Price MomentumStock underperformed, dropping 49.5% over 1Y
- ●Earnings DeclineEPS (TTM) has contracted by 32.8% YoY
- ●Rising Receivables vs SalesReceivables grew 55.3% outpacing sales growth of 24.1%
Latest MANGALAM GLOBAL ENT News
What changed recently?
Recent events, corporate actions, and announcements.
MANGALAM GLOBAL ENT valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for MANGALAM GLOBAL ENT, framed against the sector median so the premium or discount is obvious at a glance.
MANGALAM GLOBAL ENT trades at a P/E of 10.31× and P/B of 1.96×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
MANGALAM GLOBAL ENT technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for MANGALAM GLOBAL ENT — derived from the latest tape, not yesterday's close.
MANGALAM GLOBAL ENT last traded at ₹15.53 with an intraday range of ₹15.53–₹16.2 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹15.53| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 17.32 | +1.79 | +11.50% |
| R3 | 16.65 | +1.12 | +7.19% |
| R2 | 16.42 | +0.89 | +5.75% |
| R1 | 15.98 | +0.45 | +2.88% |
| PIVOT | 15.75 | 0.22 | 1.44% |
| CURRENT | 15.53 | — | — |
| S1 | 15.31 | -0.22 | -1.44% |
| S2 | 15.08 | -0.45 | -2.88% |
| S3 | 14.64 | -0.89 | -5.75% |
| S4 | 13.97 | -1.56 | -10.07% |
MGEL is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹15.94–₹16.2
Trading Below opening range, showing Bearishness
MANGALAM GLOBAL ENT financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for MANGALAM GLOBAL ENT — consolidated or standalone — with margins, YoY growth and key ratios inline.
MANGALAM GLOBAL ENT reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹511.14 Cr. and reported EPS of ₹0.26.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 2,281 | 3,384 ▲ 48.3% |
| Sales Growth YoY %Derived | 24.07% | 48.35% |
| Other Income | 21 | 16 ▼ 24.2% |
| Total Income | 2,303 | 3,401 ▲ 47.7% |
| 2,203 | 3,286 ▲ 49.1% | |
| Gross ProfitDerived | 78 | 98 ▲ 25.7% |
| Gross Margin %Derived | 3.43% | 2.90% |
| 34 | 37 ▲ 10.0% | |
| EBITDA (Operating Profit)Derived | 44 | 61 ▲ 37.7% |
| OPM %Derived | 1.94% | 1.80% |
| 30 | 44 ▲ 48.0% | |
| Profit Before Tax (PBT) | 31 | 55 ▲ 73.6% |
| 8 | 9 ▲ 12.4% | |
| Effective Tax %Derived | 26.53% | 17.18% |
| Total Profit for Period | 23 | 45 ▲ 95.8% |
| Less: Non-controlling Interests | — | — |
| Net Profit (Owner's PAT)Derived | 23 | 45 ▲ 95.8% |
| Net Profit Margin %Derived | 1.01% | 1.34% |
| PAT Growth YoY %Derived | 14.32% | 95.75% |
| Earnings Per Share (EPS ₹) | 0.70 | 1.37 ▲ 95.7% |
| Diluted Shares Outstanding (Cr) | 33 | 33 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -1 | 2 ▲ 222.5% |
| Total Expenses (incl. D&A & Interest) | 2,271 | 3,346 ▲ 47.3% |
| Material Cost % of RevenueDerived | 23.91% | 53.87% |
| Employee Cost % of RevenueDerived | 0.26% | 0.25% |
| Other Cost % of RevenueDerived | 1.22% | 0.85% |
| Interest Coverage (x)Derived | 1.41x | 1.90x |
| Period | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | 960 | 1,277 ▲ 33.1% | 1,425 ▲ 11.6% | 1,839 ▲ 29.0% | 2,281 ▲ 24.1% | 3,384 ▲ 48.3% | |
| Sales Growth YoY %Derived | — | 33.12% | 11.58% | 29.02% | 24.07% | 48.35% | |
| Other Income | 5 | 6 ▲ 14.5% | 5 ▼ 11.8% | 14 ▲ 164.8% | 21 ▲ 54.4% | 16 ▼ 24.2% | |
| Total Income | 965 | 1,283 ▲ 33.0% | 1,430 ▲ 11.5% | 1,853 ▲ 29.5% | 2,303 ▲ 24.3% | 3,401 ▲ 47.7% | |
905 | 1,224 ▲ 35.2% | 1,340 ▲ 9.5% | 1,766 ▲ 31.7% | 2,203 ▲ 24.8% | 3,286 ▲ 49.1% | ||
| Gross ProfitDerived | 54 | 54 ▼ 1.3% | 85 ▲ 58.3% | 73 ▼ 14.0% | 78 ▲ 7.1% | 98 ▲ 25.7% | |
| Gross Margin %Derived | 5.66% | 4.20% | 5.96% | 3.97% | 3.43% | 2.90% | |
44 | 43 ▼ 0.3% | 57 ▲ 30.1% | 38 ▼ 33.6% | 34 ▼ 10.0% | 37 ▲ 10.0% | ||
| EBITDA (Operating Profit)Derived | 11 | 10 ▼ 5.2% | 28 ▲ 178.7% | 35 ▲ 25.2% | 44 ▲ 25.2% | 61 ▲ 37.7% | |
| OPM %Derived | 1.12% | 0.79% | 1.99% | 1.93% | 1.94% | 1.80% | |
10 | 17 ▲ 70.8% | 16 ▼ 3.8% | 30 ▲ 84.0% | 30 ▼ 1.3% | 44 ▲ 48.0% | ||
| Profit Before Tax (PBT) | 6 | 4 ▼ 24.3% | 16 ▲ 257.2% | 23 ▲ 40.8% | 31 ▲ 38.9% | 55 ▲ 73.6% | |
1 | 1 ▼ 26.4% | 3 ▲ 281.4% | 2 ▼ 28.1% | 8 ▲ 244.1% | 9 ▲ 12.4% | ||
| Effective Tax %Derived | 20.24% | 19.66% | 20.99% | 10.71% | 26.53% | 17.18% | |
| Total Profit for Period | 5 | 4 ▼ 23.7% | 13 ▲ 251.3% | 20 ▲ 59.2% | 23 ▲ 14.3% | 45 ▲ 95.8% | |
| Less: Non-controlling Interests | -1 | -1 ▲ 21.9% | — ▲ 100.0% | — | — | — | |
| Net Profit (Owner's PAT)Derived | 6 | 4 ▼ 23.4% | 13 ▲ 195.1% | 20 ▲ 59.2% | 23 ▲ 14.3% | 45 ▲ 95.8% | |
| Net Profit Margin %Derived | 0.59% | 0.34% | 0.89% | 1.10% | 1.01% | 1.34% | |
| PAT Growth YoY %Derived | — | -23.43% | 195.07% | 59.17% | 14.32% | 95.75% | |
| Earnings Per Share (EPS ₹) | 0.20 | 0.14 ▼ 30.0% | 0.40 ▲ 185.7% | 0.61 ▲ 52.5% | 0.70 ▲ 14.8% | 1.37 ▲ 95.7% | |
| Diluted Shares Outstanding (Cr) | 29 | 30 ▲ 3.7% | 32 ▲ 6.5% | 33 ▲ 4.1% | 33 ▲ 0.0% | 33 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -0 | 0 ▲ 352.5% | 1 ▲ 200.5% | 0 ▼ 95.4% | -1 ▼ 1981.2% | 2 ▲ 222.5% | |
| Total Expenses (incl. D&A & Interest) | 959 | 1,279 ▲ 33.4% | 1,414 ▲ 10.6% | 1,830 ▲ 29.4% | 2,271 ▲ 24.1% | 3,346 ▲ 47.3% | |
| Material Cost % of RevenueDerived | 62.06% | 53.58% | 35.89% | 43.48% | 23.91% | 53.87% | |
| Employee Cost % of RevenueDerived | 0.65% | 0.55% | 0.52% | 0.33% | 0.26% | 0.25% | |
| Other Cost % of RevenueDerived | 3.90% | 2.85% | 3.45% | 1.71% | 1.22% | 0.85% | |
| Interest Coverage (x)Derived | 1.11x | 0.61x | 1.83x | 1.28x | 1.41x | 1.90x |
MANGALAM GLOBAL ENT segment analysis : revenue and profit mix.
Disclosed business segments at MANGALAM GLOBAL ENT with their share of revenue and profit, switchable between consolidated and standalone reporting.
MANGALAM GLOBAL ENT discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for MANGALAM GLOBAL ENT.
Our AI distills the core fundamental drivers supporting MANGALAM GLOBAL ENT, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
MANGALAM GLOBAL ENT's investment case rests on 9 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
The company exhibits robust promoter confidence with a significant promoter holding of 71.5%, indicating strong insider belief in its long-term prospects and stability, which is a positive signal for investors.
Mangalam Global Enterprise demonstrates healthy profitability with a Return on Equity (ROE) of 14.60% and Return on Capital Employed (ROCE) of 16.80%, reflecting efficient capital utilization and value creation.
The company has shown strong operational performance with a substantial 25.40% growth in quarterly sales, indicating increasing market demand and effective revenue generation strategies.
Profitability is on an upward trend, evidenced by a 12.10% increase in quarterly profit, showcasing the company's ability to translate sales growth into improved bottom-line results.
Valuation appears attractive with a Stock P/E of 18.60, which is notably below the sector P/E of 22.01, suggesting potential undervaluation compared to industry peers.
Key Risks.
The company carries a relatively high debt burden, with a Debt-to-Equity ratio of 1.03, which could pose financial risk and limit future borrowing capacity for expansion.
A very low Operating Profit Margin (OPM) of 1.65% indicates thin operational efficiency and vulnerability to cost pressures, potentially impacting overall profitability.
The stock has experienced significant price depreciation, trading substantially below its 52-week high of 33.48, reflecting investor concerns or market underperformance.
Mangalam Global Enterprise has a relatively small market capitalization of 487 Cr compared to its larger peers, which might limit its market influence and access to capital.
The minimal institutional investor participation, with FII holding at 0.72% and DII at 0.00%, suggests a lack of confidence from major financial institutions.
Flip Conditions.
Valuation risk. a P/E above 13 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.09. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 12% would indicate weaker capital compounding.
MANGALAM GLOBAL ENT peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — MANGALAM GLOBAL ENT is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
MANGALAM GLOBAL ENT chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for MANGALAM GLOBAL ENT — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
MANGALAM GLOBAL ENT delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for MANGALAM GLOBAL ENT over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in MANGALAM GLOBAL ENT stood at 71.5% of traded volume, against a 20-day average of 67.8%.
MANGALAM GLOBAL ENT announcements: results, concalls, ratings, M&A.
Filings MANGALAM GLOBAL ENT sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
MANGALAM GLOBAL ENT files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 87 documents below.
Copy of Newspaper Publication
Mangalam Global Enterprise Limited has informed the Exchange regarding Newspaper Advertisements for Notice of Postal Ballot.
Shareholders meeting
Mangalam Global Enterprise Limited has informed the Exchange regarding Notice of Postal Ballot.
Appointment
Mangalam Global Enterprise Limited has informed the Exchange regarding Appointment of Mr. Ramesh Kumar Agrawal as a Non- Executive Independent…
Outcome of Board Meeting
Mangalam Global Enterprise Limited has informed the Exchange regarding Outcome of Board Meeting held on Tuesday, September 08, 2026.
Press Release
Mangalam Global Enterprise Limited has informed the Exchange regarding a press release dated September 02, 2026, titled "Mangalam Global Enterprise…
Investor decks & rating reports.
MANGALAM GLOBAL ENT dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue MANGALAM GLOBAL ENT has declared, sequenced by announce and record date.
MANGALAM GLOBAL ENT corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
MANGALAM GLOBAL ENT insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in MANGALAM GLOBAL ENT as reported to SEBI — buying and selling signals from the people who know the business best.
MANGALAM GLOBAL ENT insider activity below tracks 7 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Vipin Prakash Mangal | Insider | 23 Mar 2026 | buy | +3.10 L | ₹35.96 L | ₹11.60 |
| Vipin Prakash Mangal | Insider | 23 Mar 2026 | buy | +37.25 L | ₹4.29 Cr. | ₹11.53 |
| Vasrsha Biswajit Adhikari | Insider | 20 Mar 2026 | buy | +10.0 K | ₹1.04 L | ₹10.44 |
| Praveen Kumar Gupta | Insider | 13 Jun 2025 | sell | −30.0 K | ₹4.5 L | ₹15.00 |
| Praveen Kumar Gupta | Insider | 31 Dec 2024 | sell | −10.0 K | ₹2.85 L | ₹28.50 |
| Pritu Gupta | Insider | 30 Dec 2024 | sell | −30.0 K | ₹8.36 L | ₹27.87 |
| Pritu Gupta | Insider | 27 Dec 2024 | sell | −6.7 K | ₹1.77 L | ₹26.50 |
About MANGALAM GLOBAL ENT: business, sector, key facts.
What MANGALAM GLOBAL ENT does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
MANGALAM GLOBAL ENT operates in the Other Agricultural Products industry under the Fast Moving Consumer Goods sector, listed as NSE: MGEL, BSE: 544273.
Mangalam Global Enterprise Limited (MGEL) is an Indian company primarily engaged in the manufacturing, trading, and importing of edible and non-edible oils, as well as various agricultural products within India and on the global market. Their operations span a significant portion of the agricultural commodity sector, demonstrating a diverse portfolio of goods.
A core component of MGEL's business involves the processing and sale of oilseeds and their byproducts. This includes the production of various oils such as soya oil, mustard oil, and refined castor oil. Beyond the oils themselves, they also trade in the resulting meals and cakes, including soya meal, soya de-oiled cake, mustard meal, mustard de-oiled cake, and castor de-oiled cake. These byproducts often find use in animal feed or other industrial applications.
In addition to oilseeds, MGEL's agricultural product line extends to cotton, encompassing cotton bales, cotton cake (used in cattle feed), and cotton wash oil. The company also processes and trades in other major staple crops such as wheat and rice, highlighting their broad reach within the agricultural sector.
MGEL's business model incorporates both domestic and international trade. They export a significant portion of their produced goods, expanding their market reach beyond India. Furthermore, they offer a range of supplementary services, including agency services and the trading of other agro-commodities and general merchandise, indicating a strategic approach to diversification within the agricultural and related industries.
The company markets some of its refined oils under the brand name LAGNAM, specifically refined soyabean oil, refined vegetable oil, and pungent mustard oil. This suggests an attempt to build brand recognition and potentially command a premium price for select products within their portfolio. MGEL's history dates back to 1942, demonstrating a long-standing presence and experience within the Indian agricultural commodity market.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AJOONI BIOTECH (AJOONI) Share PricePeer
- AMIRCHAND (AMIRCHAND) Share PricePeer
- ANNAPURNA SWADISHT (ANNAPURNA) Share PricePeer
- BNALTD (BNALTD) Share PricePeer
- BOMBAY SUPER HYBRID SEEDS (BSHSL) Share PricePeer
- Other undervalued NSE stocksScreener
- Quality + Value Portfolio strategyStrategy
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
Questions investors ask about MANGALAM GLOBAL ENT (MGEL).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of MANGALAM GLOBAL ENT (MGEL)?
The current share price of MANGALAM GLOBAL ENT (MGEL) is ₹15.53. Today, the stock has declined by ₹0.33 (2.08%), trading in a range of ₹15.53 to ₹16.20. The stock opened at ₹16.20 with a trading volume of 1,39,466 shares.
02Is MANGALAM GLOBAL ENT stock a good investment for long-term?
MANGALAM GLOBAL ENT can be considered for long-term investment based on several factors. The company has a market capitalization of ₹511.14 Cr., P/E ratio of 10.31, ROE of 17.49%, and ROCE of 14.92%. The dividend yield stands at 0.06%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of MANGALAM GLOBAL ENT stock?
The 52-week high price of MANGALAM GLOBAL ENT (MGEL) is ₹18.40, while the 52-week low is ₹9.53. Currently trading at ₹15.53, the stock is 62.96% above its 52-week low and 15.6% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy MANGALAM GLOBAL ENT stock at the current price?
Whether to buy MANGALAM GLOBAL ENT stock at ₹15.53 depends on multiple factors. The stock is currently trading with a P/E ratio of 10.31 and P/B ratio of 1.96. Today's performance shows a loss of 2.08%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of MANGALAM GLOBAL ENT and when is the next dividend?
MANGALAM GLOBAL ENT offers a dividend yield of 0.06%, which means for every ₹100 invested at the current price of ₹15.53, you can expect to receive approximately ₹0.06 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of MANGALAM GLOBAL ENT?
MANGALAM GLOBAL ENT's key financial metrics include: P/E Ratio: 10.31, P/B Ratio: 1.96, ROE: 17.49%, ROCE: 14.92%, Dividend Yield: 0.06%, EPS: ₹0.26, Book Value: ₹7.53, and Debt-to-Equity: 0.59. The company's market cap stands at ₹511.14 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is MANGALAM GLOBAL ENT stock performing today in the market?
MANGALAM GLOBAL ENT stock opened at ₹16.20 and is currently trading at ₹15.53, showing a decline of ₹0.33 (2.08%). The intraday high is ₹16.20 and low is ₹15.53. The trading volume stands at 1,39,466 shares, indicating moderate market participation today.
08What is the P/E ratio of MANGALAM GLOBAL ENT and what does it indicate?
MANGALAM GLOBAL ENT has a Price-to-Earnings (P/E) ratio of 10.31, which means investors are willing to pay 10.31 for every ₹1 of earnings. With an EPS of ₹0.26, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about MANGALAM GLOBAL ENT (MGEL) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.